Aequus Pharmaceuticals (FRA:AEQ) Total Liabilities : €4.71 Mil (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Aequus Pharmaceuticals Total Liabilities?

Aequus Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2024 was €4.71 Mil.

Aequus Pharmaceuticals's quarterly Total Liabilities increased from Mar. 2024 (€4.11 Mil) to Jun. 2024 (€4.49 Mil) and increased from Jun. 2024 (€4.49 Mil) to Sep. 2024 (€4.71 Mil).

Aequus Pharmaceuticals's annual Total Liabilities increased from Dec. 2021 (€1.77 Mil) to Dec. 2022 (€2.14 Mil) and increased from Dec. 2022 (€2.14 Mil) to Dec. 2023 (€3.68 Mil).

Aequus Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Aequus Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aequus Pharmaceuticals Total Liabilities Chart

Aequus Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

1.74

1.64

1.77

2.14

3.68

Aequus Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															3.30	3.68	4.11	4.49	4.71

Aequus Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Aequus Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3.278	+	(0.399	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	3.68

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	0.742	-	-2.935
	=	3.68

Aequus Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4.381	+	(0.327	+	-5.5511151231258E-17
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	4.71

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	0.571	-	-4.137
	=	4.71

Aequus Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Aequus Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Aequus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aequus Pharmaceuticals Inc (FRA:AEQ) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

AQSZF:USA AQS:Canada

Address

200 Granville Street, Suite 2820, Vancouver, BC, CAN, V6C 1S4

Website

https://www.aequuspharma.ca

Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The Company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products, namely Tacrolimus IR and Vistitan.

Aequus Pharmaceuticals Headlines

No Headlines